SCHEMBL25801595

SCHEMBL25801595

CC(C)C1CCC(C(=O)NCCC[Si](C(C)C)(C(C)C)C(C)C)CC1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ROCK2 O75116 1/20 0.43
ROCK1 Q13464 1/20 0.43
NAAA Q02083 1/20 0.42
LMNA P02545 2/20 0.39
TDP1 Q9NUW8 1/20 0.39
GNAI3 P08754 1/20 0.39
GNAO1 P09471 1/20 0.39
GNAI1 P63096 1/20 0.39
ALDH1A1 P00352 5/20 0.39
TSHR P16473 2/20 0.39
MAPT P10636 1/20 0.38
MTNR1A P48039 2/20 0.38
MTNR1B P49286 2/20 0.38
HSD17B10 Q99714 1/20 0.37
HPGD P15428 1/20 0.37
CYP3A4 P08684 2/20 0.35
GAA P10253 1/20 0.35
KDM4E B2RXH2 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25801608 0.91 ROCK2 (0.46) ROCK2ROCK1NAAALMNATDP1
SCHEMBL25801740 0.83 NAAA (0.57) ROCK2ROCK1NAAALMNAGNAI3
SCHEMBL25801602 0.83 ROCK2 (0.47) ROCK2ROCK1LMNATDP1TSHR
SCHEMBL25801593 0.82 ROCK2 (0.42) ROCK2ROCK1NAAALMNATDP1
SCHEMBL24202420 0.81 NAAA (0.64) NAAAGNAI3GNAO1GNAI1ALDH1A1
SCHEMBL25801598 0.81 HSD17B10 (0.48) ROCK2ROCK1NAAALMNATDP1
SCHEMBL10270570 0.79 ROCK2 (0.45) ROCK2ROCK1NAAALMNATDP1
SCHEMBL20900508 0.78 NAAA (0.41) ROCK2ROCK1NAAALMNATDP1
SCHEMBL10270126 0.78 HSD17B10 (0.57) ROCK2ROCK1NAAALMNATDP1
SCHEMBL22509724 0.78 HSD17B10 (0.57) ROCK2ROCK1NAAALMNATDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11696959-B2 Nanoparticle-cell construct with platinum anti-cancer agent CITY OF HOPE (US) 2023-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11696959-B2 Nanoparticle-cell construct with platinum anti-cancer agent CD47, TP53, CD63 ROCK2 2310/4885ROCK1 1926/4885NAAA 3354/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.